<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210470</url>
  </required_header>
  <id_info>
    <org_study_id>IRX-2 2005-A</org_study_id>
    <nct_id>NCT00210470</nct_id>
  </id_info>
  <brief_title>A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer</brief_title>
  <official_title>A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRX Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IRX-2 is designed to activate your own body's immune system so that it can better fight the
      invasion of head and neck cancer. In pre-clinical studies, IRX-2 has been shown to activate a
      number of different cells of the immune system.

      IRX-2 was previously tested in a study of 13 patients with advanced head and neck cancer who
      had been previously treated and failed chemotherapy and/or radiation therapy. The trials were
      specifically designed to test the safety of IRX-2. Researchers found that IRX-2 did not
      appear to have major side effects. Also, the researchers believed that further study in less
      advanced head and neck cancer patients could be useful in obtaining more data on the safety
      of IRX-2 as well as data on possible effects on tumors and on patient survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IRX-2 is a biologic product that contains multiple cytokines produced under pharmaceutical
      standards from phytohemagglutinin (PHA) stimulated mononuclear cells obtained from normal
      healthy donors. The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an
      initial low dose of cyclophosphamide and a 3-week course of indomethacin and zinc
      supplementation.

      The present study is based in large part on observations made during an exploratory Phase 1-2
      study of the safety and efficacy of the IRX-2 regimen performed at the Instituto Nacional de
      Cancerologia (INCAN), Mexico's National Cancer Institute. Patients with head and neck (HN)
      squamous cell carcinoma (SCC) were treated with the IRX-2 regimen, some as neoadjuvant
      therapy prior to surgery and some for advanced disease. Three different doses and dose
      schedules were studied. Evaluation of clinical safety included regular clinical and
      laboratory evaluations. In the patients treated before surgery, evaluation of tumor response
      was undertaken by comparison of tumor size before and after the IRX-2 regimen. This study
      provided preliminary evidence of the safety and possible efficacy of IRX-2 in the
      pre-surgical, neoadjuvant treatment of HN SCC. The regimen was well tolerated in most
      patients, and histological and clinical tumor responses were observed.

      The current study utilizes the same IRX-2 regimen evaluated in a more recent Phase 1 trial in
      patients with recurrent, refractory HN SCC performed at INCAN and the University of Kentucky,
      where the safety of the IRX-2 regimen was studied and some evidence of clinical activity was
      observed in 2 of 10 refractory patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>Enrollment through 30 days post-surgery</time_frame>
    <description>The frequency of all Adverse Events (greater than 5%) is reported. All Serious Adverse Events were described. The number of deaths during study and their relatedness (or not) to treatment, as well as changes in laboratory measures, were published (see referenced publication for details: Wolf, 2011).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and Histological Tumor Responses</measure>
    <time_frame>At approx. 21 days, prior to surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Patient Tolerance of Surgery and Post-operative Adjuvant Therapy;</measure>
    <time_frame>Following surgery and post-operative therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Competence as Measured by Lymphocyte Infiltration</measure>
    <time_frame>At approx. 21 days, prior to surgery</time_frame>
    <description>To assess measures of immune competence following administration of the IRX-2 regimen, including total lymphocyte count, peripheral T-cell count and subpopulation studies, and skin test reactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Time from cyclophosphamide administration and time from surgery to death or confirmed recurrent or progressive disease</time_frame>
    <description>Estimate disease-free survival (DFS) (defined as time from cyclophosphamide administration and time from surgery to death or clinically apparent, biopsy confirmed recurrent or progressive disease after the completion of initial therapy; margins of resection positive for tumor will not be considered disease recurrence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from cyclophosphamide administration and time from surgery to death or confirmed recurrent or progressive disease</time_frame>
    <description>Estimate overall survival (OS) in patients receiving the IRX-2 regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Tumor Response or Immune Competence (Lymphocyte Infiltration) With Disease-Free Survival or Overall Survival</measure>
    <time_frame>Time from cyclophosphamide administration and time from surgery to death or confirmed recurrent or progressive disease</time_frame>
    <description>Investigate whether clinical or histological tumor response or improvement in immune competence correlate with DFS and OS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>IRX-2 Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin and zinc supplementation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IRX-2</intervention_name>
    <description>IRX-2 for 10 days (2 s.c. injections of 1 mL each day), 1 initial injection of cyclophosphamide, and 3 weeks of indomethacin (tablets or injection) and zinc supplementation (multivitamin tablet)</description>
    <arm_group_label>IRX-2 Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Single i.v. injection of low-dose (300 mg/m2) on Day 1</description>
    <arm_group_label>IRX-2 Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>21 days of oral indomethacin, 25 mg. 3 times daily</description>
    <arm_group_label>IRX-2 Regimen</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>21 days of zinc gluconate (65 mg) as part of an oral multivitamin</description>
    <arm_group_label>IRX-2 Regimen</arm_group_label>
    <other_name>zinc gluconate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>21 days of 20 mg. orally</description>
    <arm_group_label>IRX-2 Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed (histology) Squamous Cell Carcinoma of the oral cavity,
             oropharynx, hypopharynx, or larynx.

          -  No prior surgery, radiation therapy or chemotherapy of this tumor other than biopsy or
             emergency procedure required for supportive care.

          -  Clinically staged Stage II, III, or IVA cancer, assessed to be surgically resectable
             with curative intent.

          -  Life Expectancy of greater than 6 months

        Exclusion Criteria:

          -  Stage IVB Squamous Cell Carcinoma

          -  Use of any investigational agent within the previous 30 days

          -  Uncontrolled cardiovascular disease

          -  Myocardial infarction within the last 3 months

          -  Abnormal hemoglobin, neutrophil, lymphocyte or platelet counts

          -  Positive for hepatitis B or C or HIV

          -  Evidence of distant metastases

          -  Clinical gastritis or peptic ulcer within the last 6 months

          -  Stroke within the last six months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey S. Moyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.irxtherapeutics.com</url>
    <description>IRX Therapeutics website</description>
  </link>
  <reference>
    <citation>Schilling B, Harasymczuk M, Schuler P, Egan JE, Whiteside TL. IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. J Mol Med (Berl). 2012 Feb;90(2):139-47. doi: 10.1007/s00109-011-0813-8. Epub 2011 Sep 14.</citation>
    <PMID>21915712</PMID>
  </reference>
  <reference>
    <citation>Czystowska M, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Whiteside TL. Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. Cancer Immunol Immunother. 2011 Apr;60(4):495-506. doi: 10.1007/s00262-010-0951-9. Epub 2010 Dec 23.</citation>
    <PMID>21181158</PMID>
  </reference>
  <reference>
    <citation>Naylor PH, Hernandez KE, Nixon AE, Brandwein HJ, Haas GP, Wang CY, Hadden JW. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine. 2010 Oct 8;28(43):7054-62. doi: 10.1016/j.vaccine.2010.08.014. Epub 2010 Aug 13.</citation>
    <PMID>20708999</PMID>
  </reference>
  <reference>
    <citation>Naylor PH, Hadden JW. Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy. Ann N Y Acad Sci. 2010 Apr;1194:162-8. doi: 10.1111/j.1749-6632.2010.05475.x. Review.</citation>
    <PMID>20536465</PMID>
  </reference>
  <reference>
    <citation>Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: current and future considerations. J Oncol. 2009;2009:346345. doi: 10.1155/2009/346345. Epub 2009 Aug 9.</citation>
    <PMID>19680453</PMID>
  </reference>
  <reference>
    <citation>Czystowska M, Han J, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Signorelli K, Whiteside TL. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ. 2009 May;16(5):708-18. doi: 10.1038/cdd.2008.197. Epub 2009 Jan 30.</citation>
    <PMID>19180118</PMID>
  </reference>
  <reference>
    <citation>Bright J, Al-Shamahi A. BioPartnering Europe--15th Annual Conference. Highlights from open house and emerging company presentations--Part 1. IDrugs. 2007 Dec;10(12):855-7.</citation>
    <PMID>18041679</PMID>
  </reference>
  <reference>
    <citation>Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother. 2007 Sep;30(6):624-33.</citation>
    <PMID>17667526</PMID>
  </reference>
  <reference>
    <citation>Hadden JW, Verastegui E, Hadden E. IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans. Ann N Y Acad Sci. 2007 Sep;1112:245-55. Epub 2007 Jun 28.</citation>
    <PMID>17600288</PMID>
  </reference>
  <reference>
    <citation>Naylor PH, Quadrini K, Garaci E, Rasi G, Hadden JW. Immunopharmacology of thymosin alpha1 and cytokine synergy. Ann N Y Acad Sci. 2007 Sep;1112:235-44. Epub 2007 Jun 13.</citation>
    <PMID>17567942</PMID>
  </reference>
  <reference>
    <citation>Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):587-612. Review.</citation>
    <PMID>15538546</PMID>
  </reference>
  <reference>
    <citation>Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol. 2003 Aug;3(8):1061-71. Review.</citation>
    <PMID>12860163</PMID>
  </reference>
  <results_reference>
    <citation>Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, Hadden JW. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011 Apr;34(2):173-8. doi: 10.1097/COC.0b013e3181dbb9d8.</citation>
    <PMID>20539208</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011 Dec;33(12):1666-74. doi: 10.1002/hed.21660. Epub 2011 Jan 31.</citation>
    <PMID>21284052</PMID>
  </results_reference>
  <results_reference>
    <citation>Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother. 2012 Jun;61(6):771-82. doi: 10.1007/s00262-011-1134-z. Epub 2011 Nov 6.</citation>
    <PMID>22057678</PMID>
  </results_reference>
  <results_reference>
    <citation>Whiteside TL, Butterfield LH, Naylor PH, Egan JE, Hadden JW, Baltzer L, Wolf GT, Berinstein NL. A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2012 Jun;61(6):783-8. doi: 10.1007/s00262-011-1136-x. Epub 2011 Nov 23.</citation>
    <PMID>22109700</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>January 6, 2012</results_first_submitted>
  <results_first_submitted_qc>January 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2012</results_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>IRX-2</keyword>
  <keyword>Mouth Cancer</keyword>
  <keyword>Throat Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IRX-2 Regimen</title>
          <description>The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin and zinc supplementation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject did not continue to surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IRX-2 Regimen</title>
          <description>The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin and zinc supplementation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
        <description>The frequency of all Adverse Events (greater than 5%) is reported. All Serious Adverse Events were described. The number of deaths during study and their relatedness (or not) to treatment, as well as changes in laboratory measures, were published (see referenced publication for details: Wolf, 2011).</description>
        <time_frame>Enrollment through 30 days post-surgery</time_frame>
        <population>27 participants were entered into study and treated. All participants were included in the safety analysis.
Based on safety results, the treatment regimen was tolerated. Further clinical study was recommended to evaluate efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>IRX-2 Regimen</title>
            <description>A 2-week course of IRX-2, an initial low dose of cyclophosphamide, and a 3-week course of indomethacin and zinc supplementation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
          <description>The frequency of all Adverse Events (greater than 5%) is reported. All Serious Adverse Events were described. The number of deaths during study and their relatedness (or not) to treatment, as well as changes in laboratory measures, were published (see referenced publication for details: Wolf, 2011).</description>
          <population>27 participants were entered into study and treated. All participants were included in the safety analysis.
Based on safety results, the treatment regimen was tolerated. Further clinical study was recommended to evaluate efficacy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Event: Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event: Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event: Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event: Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event: Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event: Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event: Pneumonia Aspiration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional AE Categories w lower frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical and Histological Tumor Responses</title>
        <time_frame>At approx. 21 days, prior to surgery</time_frame>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Patient Tolerance of Surgery and Post-operative Adjuvant Therapy;</title>
        <time_frame>Following surgery and post-operative therapy</time_frame>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Competence as Measured by Lymphocyte Infiltration</title>
        <description>To assess measures of immune competence following administration of the IRX-2 regimen, including total lymphocyte count, peripheral T-cell count and subpopulation studies, and skin test reactivity</description>
        <time_frame>At approx. 21 days, prior to surgery</time_frame>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Estimate disease-free survival (DFS) (defined as time from cyclophosphamide administration and time from surgery to death or clinically apparent, biopsy confirmed recurrent or progressive disease after the completion of initial therapy; margins of resection positive for tumor will not be considered disease recurrence)</description>
        <time_frame>Time from cyclophosphamide administration and time from surgery to death or confirmed recurrent or progressive disease</time_frame>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimate overall survival (OS) in patients receiving the IRX-2 regimen</description>
        <time_frame>Time from cyclophosphamide administration and time from surgery to death or confirmed recurrent or progressive disease</time_frame>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Tumor Response or Immune Competence (Lymphocyte Infiltration) With Disease-Free Survival or Overall Survival</title>
        <description>Investigate whether clinical or histological tumor response or improvement in immune competence correlate with DFS and OS</description>
        <time_frame>Time from cyclophosphamide administration and time from surgery to death or confirmed recurrent or progressive disease</time_frame>
        <posting_date>09/2012</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Primarily from the administration of cyclophosphamide to the time of surgery, except for Serious Adverse Events (reported up to 30 days after last dose of study medication)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IRX-2 Regimen</title>
          <description>The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin and zinc supplementation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ASPIRATION PNEUMONIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>NECK ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">DRY MOUTH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">CONTUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">MYALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least 60 days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow Sponsor 60 days to review and comment on them. If Sponsor requests, the Site shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zygmund Roth, Ph.D., V.P., Regulatory Affairs and QA</name_or_title>
      <organization>IRX Therapeutics, Inc.</organization>
      <phone>631-465-2028</phone>
      <email>zroth@irxtherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

